Navigation Links
New discovery reveals fate of nanoparticles in human cells
Date:9/22/2009

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have uncovered what happens to biomimetic nanoparticles when they enter human cells. They found that the important proteins that make up the outer layer of these nanoparticles are degraded by an enzyme called cathepsin L. Scientists now have to take this phenomenon into account and overcome this process to ensure the exciting field of nanomedicine can progress. The research is published today (22 September) in ACS Nano.

Dr Raphal Lvy, a BBSRC David Phillips Fellow at the University of Liverpool and lead researcher on the project said: "We've known for some time that nanoparticles are taken into cells and there have been experiments done to establish their final destinations, but we didn't know until now what state they are in by the time they get there."

In most biological applications, nanoparticles are coated with a layer of molecules, often proteins, which determine the use of nanoparticles when they enter cells. The researchers have confirmed, in a wide range of cells, that nanoparticles are taken into a region called the endosome, where this essential coating is degraded by cathepsin L.

Dr Violaine Se, also a BBSRC David Phillips Fellow at the University of Liverpool, and joint corresponding author, added: "One of the promising applications of nanoparticles in medicine is to use them as a method to deliver therapeutic protein molecules inside cells. For these biological therapies to be effective the proteins have to be maintained with high integrity and unfortunately we have seen this compromised by the degrading action of cathepsin L."

The design of any intracellular nanodevice must now take into account the possibility of cathepsin L degradation and either bypass the endosome area all together or have some built-in inhibition of the enzyme.

Dr Lvy continued: "The methods we have developed will help with this as we can now measure the location and the state of the nanoparticle quickly and quantitatively."

Professor Douglas Kell, BBSRC Chief Executive said: "Nanotechnology is an interesting area that has the potential to push all sorts of technological boundaries. There is promise of some useful applications in biology and we've already seen some excellent results with the development of nanomagnetic technology to guide therapeutic proteins and DNA to specific sites to treat tumours, for example. Fundamental bioscience research such as this, helps drive forward nanomedicine to ensure it has a real impact on health and wellbeing in the future."


'/>"/>

Contact: Nancy Mendoza
press.office@bbsrc.ac.uk
44-179-341-3355
Biotechnology and Biological Sciences Research Council
Source:Eurekalert

Related biology technology :

1. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
2. CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
3. StoredIQ Shares Expertise at IQPCs eDiscovery Pharma, Biotech and Medical Device Conference
4. Alzheimers Drug Discovery Foundation and the Lewy Body Dementia Association Invite Scientists to Apply for LBD Grant Award Program
5. PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration
6. PTC Therapeutics Announces Drug Discovery Collaboration With Roche
7. ChemBridge Corporation and Collaborative Drug Discovery Announce Strategic Collaboration to Provide Diverse Chemical Libraries Together With Researchers Own Private Data
8. Alzheimers Drug Discovery Foundation Hosts 10th International Conference on Alzheimers Drug Discovery - September 14-15
9. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
10. Discovery of natural odors could help develop mosquito repellents
11. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... ... containing an organic compound called fulvic acid that farms, greenhouses and hydroponics operations ... grow cannabis are among the fastest growing segments of customers using this high ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome ... expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with ...
(Date:1/12/2017)... ... ... Huffman Engineering, Inc. , a leader in control systems integration, today announced ... as a chemical engineer. In his new role, Beck will use his extensive ... manufacturing and water/wastewater industries. , Prior to joining Huffman Engineering, Beck served for nine ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
Breaking Biology Technology:
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
(Date:12/22/2016)... 2016 SuperCom (NASDAQ:   ... the e-Government, Public Safety, HealthCare, and Finance sectors announced today that ... selected to implement and deploy a community-based supportive services program to ... , further expanding its presence in the state. ... This new program, which is ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
Breaking Biology News(10 mins):